Early Statin Use After Type 2 Diabetes Diagnosis Linked to Lower Dementia Risk

People newly diagnosed with type 2 diabetes who started cholesterol-lowering statins within a year of diagnosis had a lower rate of dementia over the following decade than those who never started the drugs, according to a large Danish study presented at ESC Congress 2026 in Munich and published in The Lancet Regional Health - Europe.

The findings matter because diabetes is itself a recognized risk factor for cognitive decline and dementia, and high LDL cholesterol, which statins lower, is common in people with the condition, presenter Dr. Tummas Ternhamar noted. A treatment that might chip away at that added risk, using a drug already prescribed to millions of people, would be a meaningful, low-cost intervention if the association holds up. Other diabetes drugs are also being studied for effects beyond blood sugar, such as empagliflozin, which cut inflammatory blood cell clumps in a small Vanderbilt study.

What the researchers did

Ternhamar, of Copenhagen University Hospital, and colleagues used Danish national health registers to track 132,585 people who had never taken statins before being diagnosed with type 2 diabetes between 2006 and 2019, following them through 2021. They compared three groups: people who never started a statin within five years of diagnosis, those who started within the first year, and those who started between one and five years later.

To reduce the kind of bias that often distorts observational health data, the team used a technique called a clone-censor-weight design, a statistical approach built to mimic the conditions of a randomized trial more closely than a standard observational comparison would. Over a median follow-up of 7.1 years, 2.7% of participants developed dementia.

What they found

People who started statins within a year of their diabetes diagnosis had a 15% lower relative risk of dementia over 10 years compared with those who never started treatment. Starting later, between one and five years after diagnosis, was associated with a 10% lower relative risk. The pattern held for both men and women.

In absolute terms the differences are small. According to the published paper, the estimated 10-year risk of dementia was 3.9% for people who never started a statin, 3.5% for late starters and 3.3% for early starters. Put simply, earlier appeared to be better, and any statin use looked better than none, at least in this dataset.

An important caveat

This is registry data, not a randomized controlled trial, and the ESC's independent commentator was direct about what that means. "This was an observational study, so it cannot prove that statins prevent dementia," said Professor Isabel Goncalves of the ESC Communication Committee, adding that the results "should therefore support further research and help inform discussions between patients and clinicians." People who start statins earlier may differ from those who don't in ways researchers can't fully account for, even with a statistical design built to narrow that gap: they may see doctors more regularly, manage their diabetes more closely overall, or share other health behaviors that also lower dementia risk.

That distinction, association rather than proven prevention, is the difference between a promising lead and a settled answer.

Fitting into a bigger picture

The timing lines up with a broader shift in how researchers think about dementia risk. A 2024 Lancet Commission report identified high LDL cholesterol as one of two newly recognized modifiable risk factors for dementia, alongside vision loss, adding to a list of 14 factors the commission estimated could collectively prevent or delay nearly half of dementia cases worldwide if addressed. Statins are already the standard first-line treatment for lowering LDL cholesterol, which is why this association is worth studying further.

What comes next

Confirming a causal effect would require a randomized trial specifically designed to test whether early statin use reduces dementia risk in people with type 2 diabetes, and the authors themselves write that trial evidence is needed to confirm the findings. Until then, the Danish results offer a plausible, testable hypothesis rather than a reason to change prescribing on their own. Ternhamar, however, said statins "seem to be underused in patients with type 2 diabetes, despite their protective effects against cardiovascular disease," so the findings add one more reason to make sure eligible patients get them.